DXH 900
Device
Beckman Coulter, Inc.
Total Payments
$4.1M
Transactions
388
Doctors
155
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $1.4M | 90 | 41 |
| 2020 | $827,827 | 79 | 35 |
| 2019 | $500,139 | 154 | 83 |
| 2018 | $1.3M | 65 | 16 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.9M | 118 | 97.2% |
| Consulting Fee | $49,455 | 38 | 1.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $22,834 | 4 | 0.6% |
| Travel and Lodging | $22,434 | 42 | 0.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,975 | 6 | 0.3% |
| Food and Beverage | $5,480 | 180 | 0.1% |
Payments by Type
Research
$3.9M
118 transactions
General
$114,178
270 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Sepsis | Beckman Coulter, Inc. | $1.2M | 1 |
| Pediatric MIS-C COVID-19 BARDA Trial | Beckman Coulter, Inc. | $551,365 | 0 |
| Performance of hematology instruments | Beckman Coulter, Inc. | $518,998 | 0 |
| Monocyte Distribution Width (MDW) and Predictive Analytic Algorithms for Sepsis Detection | Beckman Coulter, Inc. | $377,119 | 0 |
| NOVEL DIAGNOSTICS IN EARLY SEPSIS | Beckman Coulter, Inc. | $283,788 | 0 |
| COVID-19 Neutralizing Antibodies | Beckman Coulter, Inc. | $154,621 | 0 |
| Sepsis [MDW] Post Market Study - Time to Antibiotics | Beckman Coulter, Inc. | $139,266 | 0 |
| COVID-19 CTA | Beckman Coulter, Inc. | $125,000 | 0 |
| Sepsis MDW - Post Market | Beckman Coulter, Inc. | $112,775 | 0 |
| Consulting MDW / Danaher Sepsis | Beckman Coulter, Inc. | $75,824 | 0 |
| Monocyte sepsis study | Beckman Coulter, Inc. | $75,000 | 0 |
| MDW+COVID-19 Study | Beckman Coulter, Inc. | $62,786 | 0 |
| COVID MDW - Sepsis | Beckman Coulter, Inc. | $56,139 | 0 |
| COVID Immunity monitoring | Beckman Coulter, Inc. | $50,000 | 0 |
| Novel Diagnostics in Early Sepsis | Beckman Coulter, Inc. | $30,796 | 0 |
| Sepsis MDW Emergency Department | Beckman Coulter, Inc. | $30,451 | 0 |
| MDW in Covid-19 Sepsis | Beckman Coulter, Inc. | $28,500 | 0 |
| Reliability Study | Beckman Coulter, Inc. | $25,000 | 0 |
| Sepsis BARDA | Beckman Coulter, Inc. | $10,028 | 0 |
| Annual Review - INV | Beckman Coulter, Inc. | $1,169 | 0 |
Top Doctors Receiving Payments for DXH 900 — Page 7
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Internal Medicine | Montebello, CA | $12.12 | 1 |
| , M.D | Anatomic Pathology & Clinical Pathology | Salem, OH | $11.19 | 1 |
| , M.D | Anatomic Pathology & Clinical Pathology | Canton, IL | $11.19 | 1 |
| , MD | Anatomic Pathology & Clinical Pathology | Columbia, SC | $11.03 | 1 |
| , M.D | Anatomic Pathology & Clinical Pathology | Los Angeles, CA | $10.87 | 1 |
| , M.D | Anatomic Pathology & Clinical Pathology | Hutchinson, KS | $8.95 | 1 |
Ad
Manufacturing Companies
- Beckman Coulter, Inc. $4.1M
Product Information
- Type Device
- Total Payments $4.1M
- Total Doctors 155
- Transactions 388
About DXH 900
DXH 900 is a device associated with $4.1M in payments to 155 healthcare providers, recorded across 388 transactions in the CMS Open Payments database. The primary manufacturer is Beckman Coulter, Inc..
Payment data is available from 2018 to 2021. In 2021, $1.4M was paid across 90 transactions to 41 doctors.
The most common payment nature for DXH 900 is "Unspecified" ($3.9M, 97.2% of total).
DXH 900 is associated with 20 research studies, including "Sepsis" ($1.2M).